Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease.
Desai AV, Applebaum MA, Karrison TG, Oppong A, Yuan C, Berg KR, MacQuarrie K, Sokol E, Hall AG, Pinto N, Wolfe I, Mody R, Shusterman S, Smith V, Foster JH, Nassin M, LaBelle JL, Bagatell R, Cohn SL.
Desai AV, et al. Among authors: applebaum ma.
Cancer. 2022 Aug 1;128(15):2967-2977. doi: 10.1002/cncr.34263. Epub 2022 Jun 6.
Cancer. 2022.
PMID: 35665495
Free PMC article.